Gilles Lajoie

Has grant

Professor

University of Western Ontario
Country flagCanada

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Gilles Lajoie is a Professor at the University of Western Ontario, Canada. His research spans various areas, including proteomics, biomarker discovery for ovarian cancer, and the study of noncanonical functions in human cells. Recent articles highlight his work on extracellular vesicles, kidney function biomarkers, and the role of methyltransferases in glioblastoma.

Recent Grants

Grant: Close

A Proteomic Investigation to Determine the Clinical Potential and Biological Function of Extracellular Vesicles in Early Stage Epithelial Ovarian Cancer.

Open Date: 2022-07-01

Close Date: 2025-06-30

Grant: Close

Harnessing adipose-derived stromal cells for subcutaneous soft tissue regeneration: targeting regenerative and immunomodulatory functionality

Open Date: 2022-03-01

Close Date: 2023-02-28

Grant: Close

Infrastructure for the characterization of proteins and their modifications in health and diseases

Open Date: 2021-06-16

Close Date: 2026-06-15

Grant: Close

Development of new and innovative strategies in biological mass spectrometry and proteomics

Open Date: 2021-04-01

Close Date: 2022-03-31

Grant: Close

Development of new and innovative strategies in biological mass spectrometry and proteomics

Open Date: 2020-04-01

Close Date: 2021-03-31

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor in adults. The standard treatment achieves a median overall survival for GBM patients of only 15 months. Hence, novel therapies based on an increased understanding of the mechanistic underpinnings of GBM are desperately needed. In this study, we show that elevated expression of 28S rRNA (cytosine‐C(5))‐methyltransferase NSUN5, which methylates cytosine 3782 of 28S rRNA in GBM cells, is strongly associated with the poor survival of GBM patients. Moreover, we demonstrate that overexpression of NSUN5 increases protein synthesis in GBM cells. NSUN5 knockdown decreased protein synthesis, cell proliferation, sphere formation, migration, and resistance to temozolomide in GBM cell lines. NSUN5 knockdown also decreased the number and size of GBM neurospheres in vitro . As a corollary, mice harboring U251 tumors wherein NSUN5 was knocked down survived longer than mice harboring control tumors. Taken together, our results suggest that NSUN5 plays a protumorigenic role in GBM by enabling the enhanced protein synthesis requisite for tumor progression. Accordingly, NSUN5 may be a hitherto unappreciated target for the treatment of GBM.

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (10)

Michael Knauer

Western University

CANADA
View details

YangXin Fu

-

CANADA
View details

Stephanie Zukowski

Assistant Professor

Western University

CANADA
View details

Andrew A. House

Western University

CANADA
View details

Lauren Flynn

Professor

University of Western Ontario

CANADA
View details

Scott Roffey

Graduate Teaching Assistant

Western University

CANADA
View details

Bradley L. Urquhart

University of Western Ontario

CANADA
View details

Brian Shilton

Professor

Western University

CANADA
View details

David Edgell

University of Western Ontario

CANADA
View details

Stephen Pasternak

Associate Professor

Western University

CANADA
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.